Condition

PR-Positive Breast Cancer

ClinicalTrials.gov condition label

Clinical trials4

Recruiting2

Common interventions10

Lead sponsors shown4

Clinical trials

4 shown

Supporting Health Including Endocrine Treatment for Long DurationNCT07482384 · 2026-08-04

RECRUITING

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersNCT04886531 · 2022-07-21

RECRUITING

Fulvestrant + Neratinib In Breast CancerNCT04901299 · 2023-07-01

WITHDRAWN

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerNCT04504331 · 2020-10-13

TERMINATED

Common interventions

NERATINIBDRUG2Computed tomography (CT)DIAGNOSTIC_TEST1FULVESTRANTDRUG1InfigratinibDRUG1IopamidolDRUG1Letrozole (L) or Anastrozole (A)DRUG1Omnipaque 350DRUG1SHIELD portalBEHAVIORAL1TamoxifenDRUG1TrastuzumabDRUG1

Leading sponsors

Dana-Farber Cancer Institute1Jennifer Lee Caswell-Jin1Massachusetts General Hospital1Ruth O'Regan1

Trial status mix

RECRUITING2

TERMINATED1

WITHDRAWN1

Phase mix

PHASE22

NA1

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.